CSPC Pharmaceutical Group Limited Asset Resilience Ratio
CSPC Pharmaceutical Group Limited asset resilience ratio. CSPC Pharmaceutical Group Limited (CVG) has an Asset Resilience Ratio of 5.94% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can CSPC Pharmaceutical Group Limited fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of CSPC Pharmaceutical Group Limited (2016–2025)
Asset resilience ratio of CSPC Pharmaceutical Group Limited from 2016 to 2025. This chart shows how CSPC Pharmaceutical Group Limited's Asset Resilience Ratio has changed over time. Read CSPC Pharmaceutical Group Limited (CVG) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down CSPC Pharmaceutical Group Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of CSPC Pharmaceutical Group Limited.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €2.78 Billion | 5.94% |
| Total Liquid Assets | €2.78 Billion | 5.94% |
Asset Resilience Insights
- Limited Liquidity: CSPC Pharmaceutical Group Limited maintains only 5.94% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
CSPC Pharmaceutical Group Limited Industry Peers by Asset Resilience Ratio
Compare CSPC Pharmaceutical Group Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Virbac SA
PA:VIRP |
Drug Manufacturers - General | 0.23% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.06% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 1.97% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
CSPC Pharmaceutical Group Limited Asset Resilience Ratio by Year (2016–2025)
CSPC Pharmaceutical Group Limited asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for CSPC Pharmaceutical Group Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 5.94% | €2.78 Billion ≈ $3.25 Billion |
€46.70 Billion ≈ $54.59 Billion |
+2.63pp |
| 2024-12-31 | 3.32% | €1.47 Billion ≈ $1.72 Billion |
€44.39 Billion ≈ $51.90 Billion |
+0.99pp |
| 2023-12-31 | 2.33% | €1.08 Billion ≈ $1.26 Billion |
€46.28 Billion ≈ $54.11 Billion |
-6.23pp |
| 2022-12-31 | 8.56% | €3.57 Billion ≈ $4.18 Billion |
€41.77 Billion ≈ $48.83 Billion |
+4.40pp |
| 2021-12-31 | 4.15% | €1.44 Billion ≈ $1.69 Billion |
€34.74 Billion ≈ $40.62 Billion |
-0.95pp |
| 2020-12-31 | 5.11% | €1.54 Billion ≈ $1.79 Billion |
€30.07 Billion ≈ $35.16 Billion |
+5.10pp |
| 2019-12-31 | 0.00% | €536.00K ≈ $626.64K |
€26.32 Billion ≈ $30.77 Billion |
+0.00pp |
| 2018-12-31 | 0.00% | €441.76K ≈ $516.47K |
€23.17 Billion ≈ $27.09 Billion |
0.00pp |
| 2017-12-31 | 0.00% | €611.66K ≈ $715.10K |
€18.00 Billion ≈ $21.05 Billion |
0.00pp |
| 2016-12-31 | 0.00% | €466.51K ≈ $545.39K |
€13.22 Billion ≈ $15.45 Billion |
-- |
About CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining cap… Read more